Paper Details

  1. Home
  2. Paper Details

Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.

Author: AnanthasubramaniamKarthik, HusainZehra, KarthikeyanAarthee S, KarthikeyanVanji, PalaniGurunanthan, SalinasRafael Cabrera

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

REG-SPECT can be safely performed in CKD non-dialysis patients with excellent tolerability, minimal side effects, and favorable hemodynamic responses compared to the control group.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Pharmacokinetic studies suggest delayed clearance of Regadenoson (REG), a new selective A2A receptor agonist in chronic kidney disease (CKD). The safety of REG in large series of CKD patients in daily clinical practice remains unstudied. METHODS: Retrospective study of patients with eGF...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s12350-011-9378-8

データ提供：米国国立医学図書館（NLM）

The Safety of Regadenoson in Chronic Kidney Disease Patients

My fellow researchers, we're embarking on a journey into the realm of cardiology, specifically addressing the safety of regadenoson, a pharmacologic stress agent, in chronic kidney disease (CKD) patients. This retrospective study investigates the safety and efficacy of regadenoson in a large cohort of CKD patients who were not on hemodialysis. The research aims to assess the tolerability, side effects, and hemodynamic responses associated with regadenoson stress testing in this patient population.

Regadenoson: A Safe and Effective Stress Agent for CKD Patients

This study demonstrates the safety of regadenoson stress testing in CKD patients not on hemodialysis, providing evidence for its tolerability and minimal side effects. The study found no major adverse events or significant differences in arrhythmias between CKD patients and control subjects. The results, like a refreshing oasis in the dry landscape of CKD management, offer reassurance regarding the safety of regadenoson stress testing in this patient population.

Cardiac Health and Chronic Kidney Disease

Chronic kidney disease can impact cardiac health. This study highlights the importance of careful monitoring and appropriate management of CKD patients, including the use of pharmacologic stress agents like regadenoson. Consulting a healthcare professional and adhering to their guidance is essential for maintaining heart health.

Dr.Camel's Conclusion

This research, like a beacon of light guiding us through the complexities of CKD management, provides valuable insights into the safety and efficacy of regadenoson stress testing in CKD patients. This study offers a roadmap for healthcare professionals, ensuring that this valuable diagnostic tool can be safely utilized in this vulnerable patient population.

Date :
  1. Date Completed 2011-12-07
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21541818

DOI: Digital Object Identifier

10.1007/s12350-011-9378-8

Related Literature

Article Analysis
・Side Effects of aminophylline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.